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Tumor cells may respond to chemo- or radiotherapy byactivation of several cellular signaling cascades that in-
fluence cell survival and cell death, including activation of
cell cycle arrest, senescence or triggering of several cell death
types (i.e., mitotic catastrophe, necrosis, or apoptosis).1,2 How-
ever, tumor cells derived from solid tumors are often refrac-
tory to therapy or develop resistance during the treatment
course. This is illustrated by non-small cell lung cancer
(NSCLC), which shows a high degree of intrinsic resistance,
and by small cell lung cancer (SCLC), which often develops
resistance to treatment during the course of disease.3 In part,
defective apoptotic signaling may contribute to chemo-resis-
tance and radiotherapy resistance.1 However, it is also likely
that other cell death modes (e.g., necrosis, autophagy, and
mitotic catastrophe) and premature senescence are of equal
importance for efficient tumor cell death in response to
chemo- and radiotherapy.2 In this article, we give a brief
overview of the main apoptotic signaling pathways and their
deregulation in lung cancer (LC), and we provide some
examples of apoptosis-based therapies.
Apoptosis is distinguished by some morphological char-
acteristics (i.e., plasma membrane blebbing, cell shrinkage, con-
densation/fragmentation of the chromatin, and disintegration of
the cell into apoptotic bodies). All these characteristics are
effects of selective proteolysis of proteins involved in cell
signaling, DNA repair, or structural maintenance of DNA integ-
rity, carried out by caspases, a group of cystein-aspartate en-
zymes.4 Caspases are classified as initiator caspases (caspase-2,
-8, -9, and -10 within human cells), which, upon activation,
cleave and activate the second group, the effector caspases
(mainly caspase-3, -6, and -7 within human cells), then perform
selective proteolysis.4
Caspases are activated either by death receptor (DR)
activation (extrinsic) or via mitochondrial release of apopto-
genic proteins (e.g., cytochrome c, smac/DIABLO, and HtrA2/
Omi) (intrinsic) (Figure 1). The signals propagated by the
intrinsic pathway may also be generated in cell nuclei or
lysosomes or within the endoplasmatic reticulum (Fig. 1).5–7
In the extrinsic caspase activation pathway, TNF su-
perfamily ligands bind to DRs, causing oligomerization of
DRs and recruitment of adaptor proteins via a death domain.
In turn, adaptor proteins bind pro-caspase-8 via a death
effector domain (DED) allowing pro-caspase-8 to be acti-
vated, an event that is critically dependent on the adaptor
recruitment domain in the pro-caspase-8.8 Active caspase-8
then either activates pro-caspase-3 directly or amplifies the
signal through Bid-cleavage (Figure 1).9 In the intrinsic
pathway, apoptotic signals trigger increased mitochondrial
outer membrane permeability (MOMP), followed by selec-
tive release of apoptogenic proteins from the mitochondrial
inter membrane space to the cytosol (e.g., cytochrome c, Smac/
DIABLO, and HtrA2/omi), all which promote caspase activa-
tion (Fig. 1).9 Cytosolic cytochrome c forms a complex with
apoptosis protease-activating factor 1 (Apaf-1) and dATP
(i.e., the apoptosome), in which the dimerization of pro-
caspase-9 occurs, allowing its activation into caspase-9. This
is followed by pro-caspase-3 activation.8 For these to effi-
ciently result in apoptotic propagation, the concomitant alle-
viation of the caspase-blocking effect of inhibitor of apopto-
sis proteins (IAPs) is required. Hence, the release of Smac/
DIABLO and HtrA2/omi, both which block IAPs and both
which are released as a consequence of increased MOMP,
leads to increased caspase-3 activity.9 In part, MOMP is
controlled by Bcl-2 family proteins, and the anti-apoptotic
members Bcl-xL and Bcl-2 both inhibit MOMP. Accord-
ingly, pro-apoptotic members such as Bak or Bax, both which
are activated by some BH3-only proteins (Bid, Bim, Bad,
PUMA, and NOXA), can promote MOMP.10
An important regulator of mitochondria-mediated sig-
naling is the tumor suppressor p53. Thus, p53 may induce
expression of pro-apoptotic proteins (e.g., Bax, PUMA,
Apaf-1) and/or repress anti-apoptotic proteins, including
Bcl-2, in response to DNA damage.11 In addition, p53 can
re-localize to cytosol and in the same way as BH3-only
proteins trigger Bak and/or Bax activation.12,13
CASPASE ACTIVITY ADJUSTERS
Caspase activity can be restrained by inhibitor of apo-
ptosis proteins (IAPs), by heat shock proteins (HSPs), or by
changes in protein kinase signaling. Briefly, IAPs (cIAP-1,-2,
XIAP, and survivin) cause a structural block within the
substrate-binding pocket of caspases, which impede substrate
binding and target the bound caspases for proteosomal deg-
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radation.14 HSPs (HSP90, HSP70, HSP60, and HSP27) can
block caspase activity through sequestration of cytochrome c,
inhibition of Bid redistribution, or Akt dephosphorylation or by
blocking Apaf-1–mediated pro-caspase-9 or -3 activation.15
The phosphatidylinositol 3-kinase (PI3-K)/Akt-de-
pendent pathway and the Ras-activated mitogen-activated
protein kinase (MAPK) pathway both influence apoptotic
propensity.16 Although Akt and MAPK/ERK mainly are
activated by growth factors and inhibit pro-apoptotic sig-
naling, the MAPKs p38 and JNK can also be activated in
response to cellular stress (e.g., DNA damaging treat-
ments) and be either pro- or anti-apoptotic depending on
stimuli, duration, and cell type.16 Both Akt and ERK may
inhibit Bad or caspase-9 or antagonize Bim.10,17,18 JNK is
known to regulate cytochrome c release in part by promot-
ing Bax /Bak activation or complex formation or by
FIGURE 1. Apoptotic signaling pathways. Caspases are activated by extrinsic (death receptor-mediated) or intrinsic pathway
(mitochondria-mediated) signaling. Death ligands bind to their receptors (Fas-L and Fas-R) and via death domain (DD) adap-
tor proteins (FADD) are bound. Via a death effector domain (DED), the adaptor protein recruits pro-caspase-8, which gets acti-
vated. Caspase-8 thereafter directly activates pro-caspase-3, which cleaves structural proteins and inhibitor of caspase-acti-
vated DNase (ICAD), resulting in free caspase-activated DNase (CAD), which causes fragmentation of nuclear DNA. To amplify
the signal, caspase-8 may also cleave Bid into t-Bid, which can initiate mitochondria-mediated signaling. The mitochondria-
mediated pathway results in increased mitochondrial outer membrane permeability (MOMP) and release of apoptogenic pro-
teins to cytosol (cytochrome c and Smac/DIABLO). The Bcl-2 family proteins (Bcl-2, Bcl-XL, Bak, Bax, Bad, and Bid) in part
control MOMP. Within cytosol, cytochrome c forms a complex together with Apaf-1 the apoptosome, in which pro-caspase-9 is
activated. Activated caspase-9 then triggers pro-caspase-3 activation. At several levels, caspase processing and/or activity can be in-
hibited by inhibitor of apoptosis proteins (IAPs) or by heat shock proteins (HSPs). IAPs are antagonized by Smac/DIABLO. Apoptotic
signaling is also influenced by growth factor receptor signaling (exemplified by the Akt-pathway), which blocks Bad function by
inducing binding to 14-3-3 proteins. Apoptotic signals can also be initiated at other places within the cell, (exemplified by the
cell nuclei), in which p53, PUMA, NOXA, and caspase-2 gets activated on DNA damage and transmit pro-apoptotic signals to
mitochondria.
Viktorsson and Lewensohn Journal of Thoracic Oncology • Volume 2, Number 3, March 2007
Copyright © 2007 by the International Association for the Study of Lung Cancer176
inhibiting Bcl-2/Bcl-xL.19 –24 JNK also promotes expres-
sion of Bak, Bax, and Bim.25 In a similar way, p38 controls
apoptotic signaling by antagonizing or promoting the
Bcl-2 family proteins.26,27,28
ALTERATIONS IN APOPTOTIC SIGNALING
PATHWAYS IN LUNG CANCER
Loss of pro-caspase-8, FasL, or DRs expression (i.e.,
FasR or TRAIL-receptor 1) is all reported in SCLC.29,30
Moreover, increased expression of c-FLIP, a non-cleavable
homologue to caspase-8, was observed in SCLC.31 In a
patient with NSCLC, material consisting of approximately
100 specimens, somatic mutations of TRAIL receptor 2 were
found in approximately 10% of the patients.32 The TRAIL
receptor 2 mutations reported were located in the death
domain, a region required for appropriate apoptotic signal-
ing.32 However, if the mutations in TRAIL receptor 2 influ-
enced the patient response to chemo- or radiotherapy or
overall survival remains to be examined. Decreased expres-
sion of Apaf-1 was reported in NSCLC tumors compared
with normal lung, whereas pro-caspase-9 and -3 were up-
regulated.33 Enhanced expression of pro-caspase-3 was asso-
ciated with poor prognosis in resected NSCLC,34 whereas
increased caspase-3 expression and/or activity was associated
with increased survival in another study.35 The localization of
Apaf-1 to nucleus was also reported to predict survival in
patients with early-stage NSCLC.36
With respect to Bcl-2 family proteins, we reported that
radioresistant NSCLC cells display no or little Bak or Bax
activation compared with radiosensitive NSCLCs or SCLCs.37
The prognostic value of Bcl-2 for survival and/or chemo- or
radiotherapy responses among patients with lung cancer was
recently reviewed.38 Increased Bcl-2 expression was found in
certain NSCLC subtypes and was proposed to have slightly
good prognostic value.38 In the same report, Bax was found
not to have any prognostic value, even for chemotherapy
responses.38 The expression and prognostic value of IAPs and
HSPs in NSCLC has also been reviewed.39 Briefly, c-IAP-1,
XIAP, and survivin were reported to be differentially ex-
pressed in a panel of SCLC and NSCLC cell lines in a
non-tumor type-dependent manner.40 In contrast, c-IAP-2
was expressed at a significantly higher level in NSCLC lines
compared with SCLC lines.40 However, in a clinical LC
material, c-IAP-1, -2, and XIAP were reported not to corre-
late to clinically related prognostic factors (e.g., tumor size,
stage, histology, and grade) or to tumor chemotherapeutic
response.41 In contrast, a high survivin expression was re-
ported to correlate to poor prognosis and local control after
radiotherapy.42 Analysis of HSP72 and HSP27 in human
NSCLC and SCLC cell lines did not reveal any correlation to
radiosensitivity in the cell line panel.43 When examining
HSP27 and HSP70 in NSCLC clinical specimens, expression
was found in 60% of the cases, and HSP70 expression was
correlated to histopathological differentiation, clinical stages,
smoking history, or lymph node metastasis.44
It is well established that lung cancer, especially NSCLC,
is driven by increased growth factor signaling. Thus IGF-1R,
EGF-R (erbB1), or K-Ras are all often over-expressed or con-
stitutively active in NSCLC and/or SCLC and may cause in-
creased anti-apoptotic signaling.45,46 Moreover, we have also
shown that deficiency in activation of MAPKs such as JNK
and/or p38 may also contribute to impaired radiation-induced
apoptotic responses.37 Impeded JNK activity may result from
increased expression of the phosphatase MKP1/CL100 within
NSCLC cells.47
APOPTOSIS-BASED THERAPIES
Several concepts of increasing apoptotic signaling as a
way to improve chemo- and radiotherapy responses have
been introduced and are in preclinical development to allow
clinical use or have entered into clinical trials.48,49 One way is
to reactivate death receptor signaling; this strategy has been
tested for therapeutic purposes.50,51 TNF was the first
choice, and although it was capable of causing tumor cell kill,
adverse toxic side effects abolished clinical applicability.50
Instead, the TNF-related apoptosis, inducing ligand TRAIL,
which bind to TRAIL-R1 (DR4) and TRAIL-R2 (DR5/
Killer), has shown promising results in the recombinant form
alone or together with chemo- or radiotherapy.50 Another
approach that has been examined in several preclinical stud-
ies is to use agonistic TRAIL receptor monoclonal antibodies
(mAbs).51 Currently, phase I and II clinical trials with such
mAbs directed against either DR4 (HGS-ETR1) or DR5
(HGS-ETR2) are ongoing for patients with NSCLC.51 Using
a tumor-specific gene delivery of the TRAIL gene to NSCLC
cells in a xenograft mouse model, Chang et al.52 recently
showed a radiosensitizing effect involving induction of apo-
ptotic signaling, inhibition of tumor growth, and prolonged
survival of the tumor-bearing mice.
In preclinical lung cancer models, alleviation of IAP
function using either antisense or siRNA or peptides mim-
icking the endogenous IAP inhibitor Smac has been tested
either alone or in combination with chemo- or radiotherapy
and have, to some extent, been promising.14,53–55 Strategies in
which Bcl-2/Bcl-xL expression is inhibited or BH3-mimetics
applied have also been introduced. Thus, antisense against
Bcl-2 (Oblimersen) has been tested in NSCLC and other
tumor types and has reached phase III trials.56,49 Mutations in
the p53 gene, which impede its function as a transcriptional
regulator of apoptosis, are common in both NSCLC and
SCLC (50% and 70%, respectively).57 Hence, one alternative
to revert chemo- or radiotherapy resistance in lung cancer
may therefore be to restore p53 function. This has been
clinically tested in NSCLC by using wildtype-p53 gene
transfer either alone or in combination with chemotherapy.58
Preclinical development of peptides or small molecules that
can reactivate mutant p53 is also ongoing.49 However, the
clinical usefulness of such an approach awaits further studies.
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